A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

Arthritis Research and Therapy

Volumn 16, Issue 4, 2014, Pages

  Greenwald, Maria ^a   Szczepanski, Leszek ^b   Kennedy, Alastair ^c   Veenhuizen, Melissa ^d   Komocsar, Wendy J ^d   Polasek, Emery ^d   Guerrettaz, Kelly ^e   Berclaz, Pierre Yves ^d   Lee, Chin ^d  

^a Desert Medical Advances   (United States)

^b Wyzsza Szkola Spoleczno Przyrodnicza   (Poland)

^c Private practice   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; TABALUMAB; B CELL ACTIVATING FACTOR; MONOCLONAL ANTIBODY;

ABDOMINAL TENDERNESS; ADULT; AMERICAN COLLEGE OF RHEUMATOLOGY CRITERIA; ARTERIOSCLEROSIS; ARTICLE; B LYMPHOCYTE; BLEEDING; BONE NECROSIS; BRAIN CONTUSION; BRAIN ISCHEMIA; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CHEMICAL PARAMETERS; CONTROLLED STUDY; DAS28; DIABETIC KETOACIDOSIS; DISEASE ACTIVITY; DISEASE EXACERBATION; DISKITIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EUROPEAN LEAGUE AGAINST RHEUMATISM RESPONDER INDEX IN 28 JOINT; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGICAL PARAMETERS; HEPATITIS A; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTIOUS COMPLICATION; INJECTION SITE REACTION; LARYNGITIS; LUNG FIBROSIS; LUNG TUMOR; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; OSTEOMYELITIS; PANCYTOPENIA; PHARYNGITIS; PNEUMONIA; PROSTHESIS DISLOCATION; PROTEIN BLOOD LEVEL; PSOAS ABSCESS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; STOMACH ULCER; TONSILLITIS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; URINARY TRACT INFECTION; VIRAL GASTROENTERITIS; VITAL SIGN; ARTHRITIS, RHEUMATOID; DRUG EFFECTS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED;

EID: 84907270935     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0415-2     Document Type: Article

References (16)

1. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756. 10.1084/jem.189.11.1747, 10359578.
2. Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, Morelli A, Ferraccioli G. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 2008, 35:1256-1264. 18528969.
3. Kikly K, Manetta J, Smith H, Wierda D, Witcher D. Characterization of LY2127399, a neutralizing antibody for BAFF [abstract]. Arthritis Rheum 2009, 60:693.
4. Genovese MC, Fleischmann RM, Greenwald M, Satterwhite J, Veenhuizen M, Xie L, Berclaz PY, Myers S, Benichou O. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis 2013, 72:1461-1468. 10.1136/annrheumdis-2012-202775, 23268367.
5. Genovese MC, Lee E, Satterwhite J, Veenhuizen M, Disch D, Berclaz PY, Myers S, Sides G, Benichou O. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2013, 72:1453-1460. 10.1136/annrheumdis-2012-202864, 23599435.
6. Genovese MC, Bojin S, Biagini IM, Mociran E, Cristei D, Mirea G, Georgescu L, Sloan-Lancaster J. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2013, 65:880-889. 10.1002/art.37820, 23359344.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
8. Bracewell C, Isaacs JD, Emery P, Ng WF. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2009, 9:909-919. 10.1517/14712590903033919, 19522556.
9. Jin X, Ding C. Belimumab-an anti-BLyS human monoclonal antibody for rheumatoid arthritis. Expert Opin Biol Ther 2013, 13:315-322. 10.1517/14712598.2012.758248, 23268610.
10. van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010, 37:558-567. 10.3899/jrheum.090856, 20110520.
11. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011, 13:R141. 10.1186/ar3455, 21884601.
12. Nash P, Nayiager S, Genovese MC, Kivitz AJ, Oelke K, Ludivico C, Palmer W, Rodriguez C, Delaet I, Elegbe A, Corbo M. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res 2013, 65:718-728. 10.1002/acr.21876.
13. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306:2331-2339. 10.1001/jama.2011.1692, 22056398.
14. Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev 2013, 12:1115-1117. 10.1016/j.autrev.2013.06.011, 23800448.
15. Eli Lilly & Co: Lilly discontinues one of three phase 3 rheumatoid arthritis registration studies for tabalumab: FLEX-M study did not meet efficacy expectations in an interim futility analysis; discontinuation not based on safety concerns. (press release issued 13 December 2012). [] (accessed 5 September 2014)., https://investor.lilly.com/releasedetail.cfm?releaseid=726712
16. Eli Lilly & Co: Lilly discontinues phase 3 rheumatoid arthritis program for tabalumab based on efficacy results: decision not based on safety concerns; phase 3 lupus program continues as planned (press release issued 7 February 2013). [] (accessed 5 September 2014)., https://investor.lilly.com/releasedetail.cfm?releaseid=738769